Cholangiocarcinoma

Immune-related adverse events in the TOPAZ-1 trial were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.
Read More

In 2022, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Adapting to the changes, societies such as the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, and European Society for Medical Oncology have adopted virtual and hybrid formats that deliver cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual and hybrid formats in terms of reach and impact, we are bringing the Year in Review series that seeks to disseminate key information on treatment advances to clinicians in a timely and effective manner.
Read More

Analysis of the phase 3 ABC-06 trial revealed limited prognostic utility of the tumor marker CA19.9 after initiation of FOLFOX.
Read More

Derazantinib was found to provide clinical benefit in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 mutations or amplifications.
Read More

Assessment of patient-reported outcomes revealed no clinically meaningful detriment occurred with the addition of durvalumab to gemcitabine/cisplatin in advanced biliary tract cancers.
Read More

Despite differences in baseline prognostic characteristics identified by the regional analysis of the TOPAZ-1 study, outcomes between the regions were generally similar.
Read More

The FIDES-01 clinical trial showed encouraging preliminary results for derazantinib as a second-line treatment in patients with intrahepatic cholangiocarcinoma harboring FGFR2 alterations.
Read More

NEO-GAP investigators found neoadjuvant gemcitabine/cisplatin/nab-paclitaxel combination to be feasible and safe prior to curative-intent surgical resection in patients with intrahepatic cholangiocarcinoma.
Read More

Early data from the ReFocus trial indicated that RLY-4008 may be an effective new treatment for patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Read More

Subanalysis of the phase 3 TOPAZ-1 trial found that durvalumab plus gemcitabine/cisplatin showed efficacy as a treatment regimen in patients with biliary tract cancer regardless of primary tumor location.
Read More

Page 5 of 14


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: